The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension
- PMID: 24306900
- PMCID: PMC4042511
- DOI: 10.1378/chest.13-1291
The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension
Abstract
Background: Male sex is an independent predictor of worse survival in pulmonary arterial hypertension (PAH). This finding might be explained by more severe pulmonary vascular disease, worse right ventricular (RV) function, or different response to therapy. The aim of this study was to investigate the underlying cause of sex differences in survival in patients treated for PAH.
Methods: This was a retrospective cohort study of 101 patients with PAH (82 idiopathic, 15 heritable, four anorexigen associated) who were diagnosed at VU University Medical Centre between February 1999 and January 2011 and underwent right-sided heart catheterization and cardiac MRI to assess RV function. Change in pulmonary vascular resistance (PVR) was taken as a measure of treatment response in the pulmonary vasculature, whereas change in RV ejection fraction (RVEF) was used to assess RV response to therapy.
Results: PVR and RVEF were comparable between men and women at baseline; however, male patients had a worse transplant-free survival compared with female patients (P = .002). Although male and female patients showed a similar reduction in PVR after 1 year, RVEF improved in female patients, whereas it deteriorated in male patients. In a mediator analysis, after correcting for confounders, 39.0% of the difference in transplant-free survival between men and women was mediated through changes in RVEF after initiating PAH medical therapies.
Conclusions: This study suggests that differences in RVEF response with initiation of medical therapy in idiopathic PAH explain a significant portion of the worse survival seen in men.
Figures
Comment in
-
Sex differences in response to pulmonary arterial hypertension therapy: is what's good for the goose, good for the gander?Chest. 2014 Jun;145(6):1184-1186. doi: 10.1378/chest.13-3061. Chest. 2014. PMID: 24889427 No abstract available.
Similar articles
-
Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9. doi: 10.1016/j.jacc.2011.06.068. J Am Coll Cardiol. 2011. PMID: 22133851
-
Echocardiographic parameters in patients with pulmonary arterial hypertension: correlations with right ventricular ejection fraction derived from cardiac magnetic resonance and hemodynamics.PLoS One. 2013 Aug 14;8(8):e71276. doi: 10.1371/journal.pone.0071276. eCollection 2013. PLoS One. 2013. PMID: 23967181 Free PMC article.
-
Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension.Am J Cardiol. 2008 Jun 1;101(11):1669-72. doi: 10.1016/j.amjcard.2008.01.055. Epub 2008 Apr 18. Am J Cardiol. 2008. PMID: 18489949
-
Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology.J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D22-33. doi: 10.1016/j.jacc.2013.10.027. J Am Coll Cardiol. 2013. PMID: 24355638 Review.
-
The role of the right ventricle in pulmonary arterial hypertension.Eur Respir Rev. 2011 Dec;20(122):243-53. doi: 10.1183/09059180.00006511. Eur Respir Rev. 2011. PMID: 22130817 Free PMC article. Review.
Cited by
-
Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.J Aerosol Med Pulm Drug Deliv. 2024 Oct;37(5):241-283. doi: 10.1089/jamp.2024.0016. J Aerosol Med Pulm Drug Deliv. 2024. PMID: 39388691 Review.
-
Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.Nat Cardiovasc Res. 2023 Oct;2(10):917-936. doi: 10.1038/s44161-023-00338-3. Epub 2023 Sep 28. Nat Cardiovasc Res. 2023. PMID: 39196250 Free PMC article.
-
Pulmonary Hypertension Induced by Right Pulmonary Artery Occlusion: Hemodynamic Consequences of Bmpr2 Mutation.J Am Heart Assoc. 2024 Jul 16;13(14):e034621. doi: 10.1161/JAHA.124.034621. Epub 2024 Jul 9. J Am Heart Assoc. 2024. PMID: 38979789 Free PMC article.
-
Dysregulation of the Long Noncoding RNA X-Inactive-Specific Transcript Expression in Male Patients with Pulmonary Arterial Hypertension.Am J Pathol. 2024 Aug;194(8):1592-1606. doi: 10.1016/j.ajpath.2024.04.005. Epub 2024 May 3. Am J Pathol. 2024. PMID: 38705381
-
Hydroxy-Safflower Yellow A Mitigates Vascular Remodeling in Rat Pulmonary Arterial Hypertension.Drug Des Devel Ther. 2024 Feb 20;18:475-491. doi: 10.2147/DDDT.S439686. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38405578 Free PMC article.
References
-
- Galiè N, Hoeper MM, Humbert M, et al. ; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2009;30(20):2493-2537 - PubMed
-
- van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28(10):1250-1257 - PubMed
-
- Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30(6):1103-1110 - PubMed
-
- Gomberg-Maitland M, Dufton C, Oudiz RJ, Benza RL. Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. J Am Coll Cardiol. 2011;57(9):1053-1061 - PubMed
-
- Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol. 2005;95(2):199-203 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials